Cargando…
A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which althou...
Autores principales: | Palatnik-de-Sousa, Iam, Wallace, Zachary S., Cavalcante, Stephany Christiny, Ribeiro, Maria Paula Fonseca, Silva, João Antônio Barbosa Martins, Cavalcante, Rafael Ciro, Scheuermann, Richard H., Palatnik-de-Sousa, Clarisa Beatriz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537284/ https://www.ncbi.nlm.nih.gov/pubmed/36202985 http://dx.doi.org/10.1038/s41598-022-21207-2 |
Ejemplares similares
-
A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection
por: Alves-Silva, Marcus Vinícius, et al.
Publicado: (2017) -
Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines
por: Palatnik-de-Sousa, Clarisa Beatriz
Publicado: (2019) -
Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection
por: Nico, Dirlei, et al.
Publicado: (2014) -
Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains
por: Nico, Dirlei, et al.
Publicado: (2014) -
Editorial: Epitope Discovery and Synthetic Vaccine Design
por: Palatnik-de-Sousa, Clarisa Beatriz, et al.
Publicado: (2018)